NCT02161679 (Clinical Trial/ SACITUZUMAB GOVITECAN/ IMMU-132 / HRS7-SN38)

Study Title
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer NCT02161679

Trial Description
This is a Phase II, open-label study that evaluates the safety and efficacy of IMMU-132 alone and in combination with carboplatin in patients with triple-negative breast cancer. IMMU132 will be administered once-weekly for the first 2 weeks of 3-week treatment cycles.

For those patients assigned to also receive carboplatin, will receive it on the same schedules starting 30 minutes after the completion of IMMU-132 administration. Patients may receive up to a maximum total of 8 cycles.

This trial is sponsored by Immunomedics, Inc.®.

Study Data

  • Condition: Triple Negative Breast Cancer
  • Interventions:
  • Phase: II
  • Enrollment: 80
  • Start: August 2016
  • Estimated Completion: August 2018
  • Last verified: October 2015
  • Last Updated: October 2015

Study Schematic

NCT02161679 (Clinical Trial/ SACITUZUMAB GOVITECAN/ IMMU-132 / HRS7-SN38)

Click here to Return to Drug map

Last Editorial review: November 9, 2016
Information based on (NIH/NCI) and other sources.